[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"liver-metastases-from-colorectal-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:liver-metastases-from-colorectal-cancer":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,52,97,131,157],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":4},"100636330","liver-first-bowel-first-or-simultaneous-resection-for-synchronous-colorectal-liver-metastases-outcomes-quality-of-life-and-cost-effectiveness-100636330",false,"NCT07564284","Liver-First, Bowel-First, or Simultaneous Resection for Synchronous Colorectal Liver Metastases: Outcomes, Quality of Life, and Cost-Effectiveness","Optimizing Treatment of Synchronous Colorectal Liver Metastases - Creation of a Treatment Algorithm","OPTIMAL","Inclusion Criteria:\n\n* Age over 18 years\n* Histologically proven colorectal cancer\n* Radiological evidence of liver metastases (contrast-enhanced CT or MRI), detected prior to resection of the primary colorectal tumor\n* Primary colorectal tumor (colon or rectum) in situ at time of inclusion\n* Discussed at a hepatobiliary and\u002For colorectal multidisciplinary team (MDT) meeting\n* Planned curative treatment of both the primary colorectal tumor AND the liver metastases (by resection, ablation, or transplantation)\n* Planned curative treatment of any extrahepatic disease, if present\n\nExclusion Criteria:\n\n* Unable to give informed consent (Studies 4-6 only; opt-out applies to Study 3)\n* Untreatable extrahepatic metastases at the discretion of the MDT\n* Not scheduled for curative resection of both the primary tumor and liver metastases\n* Emergency resection of the primary tumor performed prior to MDT referral","ALL","18 Years",{"count":20,"type":21},200,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn about treatment outcomes, quality of life, and healthcare costs in patients with colorectal cancer who have liver metastases detected at the same time as their primary tumor (synchronous colorectal liver metastases, CRLM). The main questions it aims to answer are:\n\nDo patients who undergo simultaneous removal of both the bowel tumor and liver metastases in one operation differ in their ability to complete the intended treatment compared to patients who undergo staged operations (bowel first or liver first)? Does the choice of surgical strategy affect quality of life and healthcare costs?\n\nPatients with synchronous CRLM discussed at a multidisciplinary team meeting at participating Swedish university hospitals will be followed prospectively for up to 5 years. Treatment is not influenced by the study - all surgical decisions are made as part of routine clinical care. Patients in the quality-of-life sub-study will complete validated questionnaires (EORTC QLQ-C30, QLQ-LM21, and QLQ-CR29) at multiple time points from diagnosis through 36 months. Healthcare costs and health literacy will also be assessed in parallel sub-studies.",[25],"Liver Metastases From Colorectal Cancer",[27,28,29,30,31,32,33,34,35,36,37,38,39],"Liver metastases","Colorectal cancer","Multidisciplinary management","Surgical strategy","Simultaneous resection","Liver first","Bowel first","Staged resections","Survival","Quality of life","Healthcare Costs","Cost-Effectiveness","Health Literacy","NOT_YET_RECRUITING","2026-04-27",{"date":43,"type":44},"2026-05-04","ACTUAL",{"date":46,"type":21},"2026-05",{"date":48,"type":21},"2029-05",{"name":50,"class":51},"Karolinska Institutet","OTHER",{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":62,"conditions":63,"keywords":72,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":96},"100635757","outcomes-after-liver-and-biliary-resection-at-a-high-volume-center-100635757","NCT07556835","Outcomes After Liver and Biliary Resection at a High-Volume Center","Ambispective Cohort Study of Clinical and Oncologic Outcomes in Patients Undergoing Liver and Biliary Resection at San Jacopo Hospital, Pistoia","BILIVER","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patients undergoing liver resection and\u002For biliary resection at San Jacopo Hospital, Pistoia\n* Diagnosis of benign or malignant hepatobiliary disease\n* Availability of clinical, surgical, and follow-up data\n* For the prospective cohort, provision of written informed consent when required according to local regulations\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Pregnancy\n* No liver or biliary resection performed\n* Biopsy only without resection\n* Refusal or unavailability of consent for the prospective cohort when consent is required",{"count":61,"type":21},1000,"The goal of this observational study is to evaluate clinical and oncologic outcomes in adult patients undergoing liver and\u002For biliary resection for benign and malignant diseases.\n\nThis study evaluates postoperative morbidity and mortality within 90 days after surgery, as well as overall survival and disease-free survival in patients with malignant disease.\n\nParticipants will:\n\n* undergo standard surgical and perioperative management according to routine clinical practice\n* have clinical, surgical, and follow-up data collected from institutional medical records\n* be followed for postoperative outcomes and long-term oncologic outcomes up to 5 years",[64,65,66,67,25,68,69,70,71],"Liver Neoplasms","Hepatobiliary Diseases","Cholangiocarcinoma","Hepatocellular Carcinoma","Liver Metastases","Biliary Tract Diseases","Benign Liver Disease","Gallbladder Carcinoma",[73,74,75,76,77,78,79,80,81,82,83,84,85,86,66],"Hepatobiliary surgery","Liver resection","Biliary resection","Hepatectomy","Postoperative complications","Postoperative mortality","Clavien-Dindo classification","Overall survival","Disease-free survival","Surgical outcomes","Observational study","Ambispective cohort","CRLM","HCC","2026-04-22",{"date":89,"type":44},"2026-04-29",{"date":91,"type":21},"2026-04",{"date":93,"type":21},"2036-12",{"name":95,"class":51},"Azienda USL Toscana Centro",1,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":107,"phases":108,"briefSummary":110,"conditions":111,"keywords":112,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":130},"100621046","sonoporation-and-tumor-microenvironment-response-in-colorectal-liver-metastases-100621046","NCT07365527","Sonoporation and Tumor Microenvironment Response in Colorectal Liver Metastases","Tumor Response to Sonoporation: A Clinical Translational RCT of Contrast-enhanced Ultrasound Induced Changes in Tumor Microenvironment of Colorectal Liver Metastases","CEUSON","Inclusion Criteria:\n\n* Adult patients (≥18 years)\n* Ability to provide written informed consent\n* Histopathological confirmed colorectal adenocarcinoma\n* Scheduled for liver resection or ablation at the Rigshospital, or admitted to oncologic treatment due to colorectal liver metastases (CLM) at Zealand University Hospital\n* Presence of at least one CLM evaluable and accessible by CEUS\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n* Follow the conditions regarding fertility, pregnancy, or lactation:\n\n  * Women of childbearing potential (WOCBP) are defined as women ranging from the period of menarche till the post-menopausal period, unless permanently sterile (e.g. hysterectomy, bilateral salpingectomy and bilateral oophorectomy), Post-menopause is defined as no menses for 12 months without an alternative medical cause.\n  * WOCBP should use a secure and highly effective birth control (as stated in the \"Recommendations related to contraception and pregnancy testing in clinical trials\", version 1.1, section 4.1, from the Clinical Trials Facilitation and Coordination Group) during the entire period of the trial. In cases of uncertainty regarding pregnancy, pregnancy testing either as highly sensitive serum or urine pregnancy test will be used.\n\nExclusion Criteria:\n\n* Oncologic systemic treatment 2 weeks prior to inclusion\n* Prior treatment with an immune checkpoint inhibitor (e.g. anti-PD-L1, anti PD-1, or anti-PD-L2)\n* Inability to reliably distinguish the study metastasis from other hepatic metastases using CEUS\n* Systemic treatment with either corticosteroids (\\>10 mg daily prednisolone equivalents) or other immunosuppressive medications within 2 weeks prior inclusion. Inhaled or topical steroids and adrenal replacements doses \\> 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.\n* Known history of human immunodeficiency virus (HIV), active or chronic hepatitis B, or C.\n* Pregnancy or lactation.\n* Confirmed dMMR positive primary tumors\n* Inability to comply with study protocol due to psychological, social, or logistical reasons.\n* Contraindications for CEUS:\n\n  * Known hypersensitivity to SonoVue® or any other ultrasound contrast agent\n  * Uncontrolled atrial hypertension\n  * Known right-to-left intracardiac shunt\n  * Severe pulmonary hypertension (SAP \\>90 mmHg)\n  * Adult respiratory distress syndrome.\n  * Known hypersensitivity to macrogols\n  * Unstable ischemic heart disease or acute coronary syndrome\n  * Severe lung disease, e.g. severe chronic obstructive lung disease",{"count":106,"type":21},48,"INTERVENTIONAL",[109],"NA","This study is an investigator-initiated, randomized controlled trial enrolling patients with colorectal liver metastases. The objectives are to evaluate the safety and efficacy of contrast-enhanced ultrasound (CEUS)-mediated sonoporation as a potential therapeutic intervention and to investigate whether sonoporation can modulate the tumor microenvironment toward a more immune-active state",[25],[113,114,115,116,117,118,119],"liver metastasis","CEUS","Sonoporation","Contrast enhanced ultrasound","colorectal cancer","liver metastases","tumor microenvironment","RECRUITING","2026-02-24",{"date":123,"type":44},"2026-02-27",{"date":125,"type":44},"2026-02-25",{"date":127,"type":21},"2027-01-15",{"name":129,"class":51},"Zealand University Hospital",2,{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":17,"minAge":138,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":96},"100606606","prospective-cohort-study-on-the-relationship-between-exosomal-peroxiredoxin-1-prdx1-and-postoperative-liver-metastasis-100606606","NCT07177742","Prospective Cohort Study on the Relationship Between Exosomal Peroxiredoxin 1 (PRDX1) and Postoperative Liver Metastasis","Prospective Cohort Study on the Relationship Between Peroxiredoxin 1 (PRDX1) in Blood Exosomes From Colorectal Cancer Radical Resection Specimens and Postoperative Liver Metastasis","Inclusion Criteria:\n\n* Age between 19-80 years old, gender not limited;\n\n  * Can comply with the requirements of the research visit plan and other protocols;\n\n    * Voluntarily participate and sign an informed consent form; ④ Diagnosed with colon adenocarcinoma through pathological examination; ⑤ Patients who have completed colorectal radical surgery.\n\nExclusion Criteria:\n\n* Patients who cannot complete radical surgery for colorectal cancer;\n\n  * Patients with liver diseases (chronic hepatitis B, hepatitis C, severe fatty liver, cirrhosis);\n\n    * Patients who require combined organ resection;\n\n      * Combine patients with other malignant tumors or blood or immune system diseases; ⑤ Prior to tumor resection, any anti-tumor treatment, including radiotherapy, chemotherapy, and molecular targeted therapy, has been performed; ⑥ After surgery, it was found that the mesenteric vein branch of the specimen could not obtain blood due to severe infiltration or other reasons.\n\n        * Patients with severe postoperative complications leading to delayed treatment (Clavien-Dindo grade III or above).","19 Months","80 Months",{"count":141,"type":21},260,"The occurrence of liver metastasis after curative surgery for resectable colorectal cancer is an important cause of death for patients. Accurately identifying high-risk patients for metastasis and intervening in them has important clinical significance. The pathological examination of surgical specimens failed to fully utilize valuable specimen information and accurately predict liver metastasis; The biomarkers secreted by tumors are metabolized in the liver through the portal vein, especially the particles such as extracellular vesicles secreted by tumors, which are ultimately diluted in peripheral blood and cannot be effectively detected. Our research group extracted an average of 11.25ml of blood (named blood derived from portal vein branch specimens, sdBlood for short) from 8 colorectal cancer radical surgery specimens. Compared with peripheral blood, protein mass spectrometry analysis revealed a significant increase in exosome proteins such as peroxidized redox protein 1 (PRDX1), which are highly correlated with metastasis. This project innovatively uses sdBlood, which has been overlooked by routine pathological examination, to detect the exosomal protein PRDX1 in sdBlood, which is significantly higher than the peripheral blood concentration. A prospective cohort study was established, including 252 patients with pathologically confirmed colorectal cancer after radical surgery. The incidence and time of liver metastasis were followed up and observed. Cox regression statistical analysis was used to determine the correlation between this marker and metastasis and determine its critical value, providing a basis for clinical diagnosis and treatment.",[144,25,145,146,147],"Colorectal Cancer","Pathology","Exosome","Peroxidized Redox Protein 1","2026-02-03",{"date":150,"type":44},"2026-02-06",{"date":152,"type":44},"2021-02-15",{"date":154,"type":21},"2026-11-30",{"name":156,"class":51},"Mu-qing Yang",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":107,"phases":167,"briefSummary":168,"conditions":169,"keywords":170,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":96},"100601357","the-role-of-the-imaging-fapi-petct-in-exploring-the-microenvironment-of-colorectal-cancer-liver-metastases-100601357","NCT07109440","The Role of the Imaging FAPI PET\u002FCT in Exploring the Microenvironment of Colorectal Cancer Liver Metastases","The Role of FAPI PET\u002FCT in Exploring the Microenvironment of Colorectal Cancer Liver Metastases: Non-randomized Phase II Molecular Imaging Study","FOAM","Inclusion Criteria:\n\n* Age above 18 years.\n* Liver metastasis on standard imaging for the initial assessment (MRI, FDG PET\u002FCT)\n* Naïve for treatment or after neoadjuvant chemotherapy\n* Scheduled for liver metastasis resection\n* ECOG Performance status ≤2.\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Non-resectable liver metastases\n* Pregnant and lactating women\n* Subjects with another significant medical condition which, in the investigator's opinion, may interfere with the completion of the study.",{"count":166,"type":21},50,[109],"FAPI PET\u002FCT molecular imaging represents a cutting-edge advancement in oncological imaging, particularly for the preoperative assessment of colorectal liver metastases (CRLM). Fibroblast activation protein inhibitors (FAPIs), which are the focus of this imaging modality, selectively target cancer-associated fibroblasts, a critical component of the tumor microenvironment. FAPI PET\u002FCT could be useful in the detection of HGP (Histological Growth Pattern) and in the changes during neoadjuvant chemotherapy prior to surgery",[25],[171,172,173,174],"liver metastases from colorectal cancer","FAPI PET\u002FCT","HGP","CAF","2025-08-06",{"date":177,"type":44},"2025-08-07",{"date":179,"type":44},"2025-05-09",{"date":181,"type":21},"2028-12",{"name":183,"class":51},"Jules Bordet Institute"]